Literature DB >> 30864008

Sacral neuromodulation in congenital lumbo-sacral and traumatic spinal cord defects with neurogenic lower urinary tract symptoms: a single-center experience in children and adolescents.

Farzaneh Sharifiaghdas1.   

Abstract

PURPOSE: This study evaluated sacral neuromodulation's effectiveness for managing refractory neuropathic lower urinary tract dysfunction in children and adolescents.
METHODS: Twenty-five children and adolescents underwent peripheral nerve evaluation test phase of sacral neuromodulation at our center. Thirteen (seven boys and six girls) cases suffered from neuropathic lower urinary tract dysfunction refractory to the maximum medical treatment. The test was done with temporary wire in all patients. Patients with more than 50% improvement in symptoms were chosen for the second stage of implantation of quadripolar tined lead and implantable pulse generator. Bowel transit symptoms were recorded before and after the surgery.
RESULTS: Eight patients (61.53%; five boys and three girls) had positive responses to the peripheral nerve evaluation test phase. They underwent implantation of permanent quadripolar tined lead and implantable pulse generator. The etiologies were lumbosacral myelomeningocele, occult spina bifida, partial sacral agenesis and incomplete spinal cord injury. Positive clinical response (> 50% improvement in symptoms) was achieved in seven (85%) at a mean follow-up of 14.25 months. Three patients became capable to stop clean intermittent catheterization (P =0.125). The 24-h pad test decreased from 484 to 78 g from before to after the surgery (P =0.043).
CONCLUSION: This clinical study on a small sample size of children and adolescents demonstrates positive results in short-term follow-up. However, as the procedure is still not approved officially, multicenter studies with more patients can prove the safety and efficacy of sacral neuromodulation in long term among this special group of patients.

Entities:  

Keywords:  Child; Congenital abnormalities; Electric stimulation therapy; Neuropathic; Urinary incontinence

Mesh:

Year:  2019        PMID: 30864008     DOI: 10.1007/s00345-019-02721-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  22 in total

Review 1.  Electrical management of neurogenic lower urinary tract disorders.

Authors:  C Joussain; P Denys
Journal:  Ann Phys Rehabil Med       Date:  2015-08-25

2.  Neuromodulation in the management of voiding dysfunction in children.

Authors:  E A Tanagho
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

3.  International Children's Continence Society's recommendations for therapeutic intervention in congenital neuropathic bladder and bowel dysfunction in children.

Authors:  Y F Rawashdeh; P Austin; C Siggaard; S B Bauer; I Franco; T P de Jong; T M Jorgensen
Journal:  Neurourol Urodyn       Date:  2012-04-24       Impact factor: 2.696

Review 4.  [Sacral neuromodulation for neurogenic bladder dysfunction].

Authors:  T M Kessler; J Wöllner; M Kozomara; L Mordasini; U Mehnert
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

5.  Factors Predicting Complications After Sacral Neuromodulation in Children.

Authors:  Molly E Fuchs; Peter L Lu; Stephanie J Vyrostek; Steven Teich; Seth A Alpert
Journal:  Urology       Date:  2017-05-16       Impact factor: 2.649

6.  Constipation in infants and children: evaluation and treatment. A medical position statement of the North American Society for Pediatric Gastroenterology and Nutrition.

Authors:  S S Baker; G S Liptak; R B Colletti; J M Croffie; C Di Lorenzo; W Ector; S Nurko
Journal:  J Pediatr Gastroenterol Nutr       Date:  1999-11       Impact factor: 2.839

7.  Influence of sacral neuromodulation on electrosensation of the lower urinary tract.

Authors:  J J Wyndaele; D Michielsen; S Van Dromme
Journal:  J Urol       Date:  2000-01       Impact factor: 7.450

8.  Preliminary results of sacral neuromodulation in 23 children.

Authors:  Mitchell R Humphreys; David R Vandersteen; Jeffery M Slezak; Pam Hollatz; Craig A Smith; Janet E Smith; Yuri E Reinberg
Journal:  J Urol       Date:  2006-11       Impact factor: 7.450

9.  Sacral neuromodulation for neurogenic bladder dysfunction in children.

Authors:  J M Guys; M Haddad; D Planche; M Torre; C Louis-Borrione; J Breaud
Journal:  J Urol       Date:  2004-10       Impact factor: 7.450

Review 10.  The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines.

Authors:  Marianne de Sèze; Alain Ruffion; Pierre Denys; Pierre-Alain Joseph; Brigitte Perrouin-Verbe
Journal:  Mult Scler       Date:  2007-03-15       Impact factor: 6.312

View more
  5 in total

1.  Is there enough evidence to support sacral neuromodulation as a viable treatment option in children and adolescents with neurogenic lower urinary tract dysfunction?

Authors:  Apostolos Apostolidis
Journal:  World J Urol       Date:  2019-06-03       Impact factor: 4.226

Review 2.  What Is New in Neuromodulation?

Authors:  Courtenay K Moore; Jessica J Rueb; Samir Derisavifard
Journal:  Curr Urol Rep       Date:  2019-08-07       Impact factor: 3.092

3.  Urodynamic evaluation of bladder function in patients with urinary incontinence secondary to congenital tethered cord syndrome after homogeneous spinal-shortening axial decompression procedure.

Authors:  Ximing Xu; Kaiqiang Sun; Jingchuan Sun; Yuan Wang; Jian Zhu; Xiaoqiu Yuan; Chenglong Ji; Yongfei Guo; Jiangang Shi
Journal:  Eur Spine J       Date:  2021-10-03       Impact factor: 3.134

4.  Systematic Literature Review and Meta-Analysis of Sacral Neuromodulation (SNM) in Patients with Neurogenic Lower Urinary Tract Dysfunction (nLUTD): Over 20 Years' Experience and Future Directions.

Authors:  Arndt van Ophoven; Stefan Engelberg; Helen Lilley; Karl-Dietrich Sievert
Journal:  Adv Ther       Date:  2021-03-13       Impact factor: 3.845

Review 5.  Is there a role for sacral neuromodulation in patients with neurogenic lower urinary tract dysfunction?

Authors:  Marcio Augusto Averbeck; Jorge Moreno-Palacios; Alejandro Aparicio
Journal:  Int Braz J Urol       Date:  2020 Nov-Dec       Impact factor: 1.541

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.